Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.

Key Takeaways Vinay Prasad is returning as head of the FDA’s Center for Biologics Evaluation and ResearchHe was reportedly removed from his position July 29 after political criticism but is now returningThe White House decided the earlier criticisms were disingenuous MONDAY,